Dapagliflozin results in more patients with improved or resolved MASH without worsening of fibrosis, improved fibrosis without worsening of MASH.

NHSBSA report shows increase in prescription items dispensed in the community in England last year The NHS Business Services Authority (NHSBSA) has published the annual Prescription Cost Analysis (PCA ...

A diabetes drug may soon double as a treatment for liver disease. Dapagliflozin, an SGLT-2 inhibitor typically used for type ...

A diabetes drug, dapagliflozin, has shown promise in treating fatty liver disease by reducing liver fat and scarring, ...

Dapagliflozin helped people reduce fat levels in their liver and avoid liver scarring that comes with the condition, which ...

HYDERABAD: The Drugs Control Administration (DCA) raided the residence of a habitual offender in Moosarambagh, Malakpet, and seized spurious drugs worth Rs 5.21 ...

Telangana Drug Control Administration seized fake antidiabetic, antihypertensive, and abortion pills worth Rs. 5.21 lakh from ...

The sodium glucose cotransporter 2 (SGLT-2) inhibitor drug dapagliflozin, widely used to treat type 2 diabetes, also shows ...

A new study reveals that dapagliflozin, a common diabetes medication, could significantly improve conditions like metabolic ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Improves fibrosis and steatohepatitis Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a broad clinical spectrum, ranging from simple steatosis to metabolic ...